NB003

NB003 is a small-molecule drug developed by Ningbo Newbay Technology Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 15 mg BID on a continuous schedule in 28-day cycles. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07379047 (Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST)), in gastrointestinal stromal tumour. The largest, NCT07379047, plans to enrol 255 participants with primary completion expected 2028-08-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.